InteRNA Technologies B.V., a Nijmegen, the Netherlands–based biopharma company engaged in the development of microRNA (miRNA)-based therapeutics for oncology, recently raised a final tranche of its Series A funding and closed it at US$10.5m.
Backers included new investors INKEF Capital and Aglaia Oncology Fund II as well as existing shareholders. In conjunction with the funding, Lucas de Breed and Karl Rothweiler for the new investors joined the Supervisory Board along with Samuel Gerssen (for Waterman 40 Holding) and new independent member Brian Bronk (Sanofi Sunrise, part of the Sanofi Global R&D organization). Hans Schikan, former CEO of Prosensa, joined as new chairman of the Supervisory Board.
The company intends to use the funds to progress several lead product candidates, through preclinical studies towards clinical development and for further expansion of the management team.
Led by Roel Schaapveld, CEO, InteRNA Technologies develops cancer therapeutics based on a proprietary technology platform for the rapid identification and validation of therapeutic miRNAs. At present, the company has established in vivo proof of concept for multiple pipeline candidates and is pursuing a proactive partnership strategy to acquire appropriate delivery technologies for its products. It expects to engage in corporate partnerships to progress several of its products into clinical development.
InteRNA Technologies was incorporated by Aglaia Oncology Fund I as a spin-off from the Hubrecht Institute, Utrecht, the Netherlands.